Literature DB >> 3499448

The corticotropin-releasing hormone test in the postoperative evaluation of patients with cushing's syndrome.

P C Avgerinos1, G P Chrousos, L K Nieman, E H Oldfield, D L Loriaux, G B Cutler.   

Abstract

After surgical cure of Cushing's syndrome most patients develop transient secondary adrenal insufficiency that lasts for approximately 1 yr. Since ACTH-secreting pituitary adenomas generally respond to ovine CRH (oCRH), we tested the hypothesis that an early postoperative response to oCRH may indicate the presence of residual pituitary tumor and, therefore, predict recurrence. We also assessed the usefulness of oCRH for monitoring the recovery of the hypothalamic-pituitary-adrenal axis and for clarifying the pathophysiology of this condition. Thirty-four patients cured of Cushing's syndrome (29 with Cushing's disease, 3 with adrenal adenomas, and 2 with the ectopic ACTH syndrome) had an evening oCRH test 1-2 weeks after surgery. Nine patients (6 with Cushing's disease, 2 with adrenal adenomas, and 1 with the ectopic ACTH syndrome) participated in a longitudinal evaluation and had repeated oCRH and 1-h ACTH tests at 2-month intervals for a year after surgery. Patients were considered to be cured on the basis of at least 3 subnormal urinary [less than 20 micrograms/24 h (less than 55 nmol/day)] or morning plasma cortisol levels [0600-0900 h; less than 6 micrograms/dL (less than 170 nmol/L)] in the first 2 weeks after surgery. The plasma ACTH and cortisol responses to oCRH in the early postoperative period were subnormal in 23 and normal in 6 patients with Cushing's disease. Three patients developed recurrent Cushing's disease (3, 3, and 23 months after transphenoidal surgery). All 3 were among the 6 who had a normal early postoperative response to oCRH. All of the 23 patients who had a subnormal response to oCRH in the early postoperative period have remained in remission for an average follow-up period of 14 months (6-42 months). Thus, the recurrence rate was significantly greater in patients with normal oCRH tests in the early postoperative period (P less than 0.001, by chi 2 analysis). Surgically cured patients with adrenal adenomas or ectopic ACTH secretion also had subnormal plasma ACTH and cortisol responses to oCRH during the early postoperative period. During longitudinal evaluation for 12 months after surgery, the ACTH and cortisol responses to oCRH increased progressively (regardless of the cause of Cushing's syndrome). Cortisol responses to oCRH correlated significantly with the cortisol responses to exogenous ACTH (r = 0.89; P less than 0.00001). We conclude that most patients with Cushing's syndrome have suppressed responses to oCRH during the early postoperative period.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499448     DOI: 10.1210/jcem-65-5-906

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Painful hypoadrenalism.

Authors:  Chisho Hoshino; Noriyuki Satoh; Masashi Narita; Akio Kikuchi; Minoru Inoue
Journal:  BMJ Case Rep       Date:  2011-03-25

3.  Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease.

Authors:  David Asuzu; Grégoire P Chatain; Christina Hayes; Sarah Benzo; Raven McGlotten; Meg Keil; Andrea Beri; Susmeeta T Sharma; Lynnette Nieman; Maya Lodish; Constantine Stratakis; Russell R Lonser; Edward H Oldfield; Prashant Chittiboina
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

4.  The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery.

Authors:  John R Lindsay; Edward H Oldfield; Constantine A Stratakis; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

5.  Transsphenoidal surgery for Cushing disease: experience with 136 patients.

Authors:  Ivan Ciric; Jin-Cheng Zhao; Hongyan Du; James W Findling; Mark E Molitch; Roy E Weiss; Samuel Refetoff; William D Kerr; Joel Meyer
Journal:  Neurosurgery       Date:  2012-01       Impact factor: 4.654

Review 6.  Management of Cushing disease.

Authors:  Nicholas A Tritos; Beverly M K Biller; Brooke Swearingen
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

7.  Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up.

Authors:  F Bakiri; S Tatai; R Aouali; M Semrouni; P Derome; F Chitour; M Benmiloud
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

8.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

9.  Postoperative testing to predict recurrent Cushing disease in children.

Authors:  Dalia L Batista; Edward H Oldfield; Margaret F Keil; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

10.  AZA-deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors.

Authors:  Maria Francesca Cassarino; Antonella Sesta; Luca Pagliardini; Marco Losa; Giovanni Lasio; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.